Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 588

The DOI matches its Crossref record.

Methotrexate in Resistant Juvenile Rheumatoid Arthritis: Results of the U.S.A.–U.S.S.R. Double-Blind, Placebo-Controlled Trial

Open access
Giannini, Edward H., Brewer, Earl J., Kuzmina, Nina, Shaikov, Alexander, Maximov, Alexei, Vorontsov, Igor, Fink, Chester W., Newman, Arthur J., Cassidy, James T., Zemel, Lawrence S.·1992·New England Journal of Medicine

Abstract

BACKGROUND: The antimetabolite methotrexate has been shown in placebo-controlled trials to be effective in adults with rheumatoid arthritis. Methotrexate may also be effective in children with resistant juvenile rheumatoid arthritis, but the supporting data are from uncontrolled trials. METHODS: Centers in the United States and the Soviet Union participated in this randomized, controlled, double-blind trial designed to evaluate the effectiveness and safety of orally administered methotrexate. Patients received one of the following treatments each week for six months: 10 mg of methotrexate per square meter of body-surface area (low dose), 5 mg of methotrexate per square meter (very low dose), or placebo. The use of prednisone (less than or equal to 10 mg per day) and two nonsteroidal antiinflammatory drugs was also allowed. RESULTS: The 127 children (mean age, 10.1 years) had a mean duration of disease of 5.1 years; 114 qualified for the analysis of efficacy. According to a composite index of several response variables, 63 percent of the children who received low-dose methotrexate improved, as compared with 32 percent of those in the very-low-dose group and 36 percent of those in the placebo group (P = 0.013). As compared with the placebo group, the low-dose group also had significantly larger mean reductions from base line in the number of joints with pain on motion (-11.0 vs. -7.1), the pain-severity score (-19 vs. -11.5), the number of joints with limited motion (-5.4 vs. -0.7), and the erythrocyte sedimentation rate (-19.0 vs. -6 mm per hour). In the methotrexate groups only three children had the drug discontinued because of mild-to-moderate side effects; none had severe toxicity. CONCLUSIONS: Methotrexate given weekly in low doses is an effective treatment for children with resistant juvenile rheumatoid arthritis, and at least in the short term this regimen is safe.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199204163261602

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 588

Metadata

Authors
Giannini, E. H., Brewer, E. J., Kuzmina, N., Shaikov, A., Maximov, A., Vorontsov, I., Fink, C. W., Newman, A. J., Cassidy, J. T., & Zemel, L. S.
Venue
New England Journal of Medicine
Published
1992-04-16
Volume
326
Issue
16
Pages
1043-1049
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2342174771
Cited by
588
References
0
FWCI
6.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Methotrexate in Resistant Juvenile Rheumatoid Arthritis: Results of the U.S.A.–U.S.S.R. Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1056/nejm199204163261602
The paper
Giannini, E. H., Brewer, E. J., Kuzmina, N., Shaikov, A., Maximov, A., Vorontsov, I., Fink, C. W., Newman, A. J., Cassidy, J. T., & Zemel, L. S. (1992). Methotrexate in Resistant Juvenile Rheumatoid Arthritis: Results of the U.S.A.–U.S.S.R. Double-Blind, Placebo-Controlled Trial. New England Journal of Medicine. https://doi.org/10.1056/nejm199204163261602

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.